Cyclerion Therapeutics (CYCN)
Holds a suspended depression-treatment system and out-licensed sGC development rights.
Something off on this page? Send us feedback.
Holds a suspended treatment-resistant-depression system and economic rights in sGC assets, earning transactional income from licensing, asset sales, and option fees rather than product sales. Operations are highly externalized, while praliciguat's progress rests with its worldwide licensee and a proposed merger remains pending.
Maintains a pre-merger portfolio centered on CYC-126, a licensed anesthetic-and-monitoring system once planned for hospital-based treatment-resistant depression, alongside economic rights in praliciguat, olinciguat licensing opportunities, and a non-controlling Tisento investment. Has no approved products or product-sale revenue, and relies on consultants and outsourced research.
Has suspended work on CYC-126 because of cash limitations while Akebia controls worldwide development and commercialization of praliciguat. A proposed all-stock reverse merger with Korsana Biosciences would shift the listed parent's primary business to Korsana if the transaction closes; current operations remain constrained by merger conditions and contractual limits on competing specified CNS-penetrant sGC programs.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.4M · Total debt $0 · Total assets $6.9M · Shareholders' equity $5.1M
- Revenue
- $0
- Operating income
- −$1.8M
- Net income
- −$1.8M
No dividends on record.
| Institutions | 70.46% | 471.2K shares | |
|---|---|---|---|
| 21 holders · as of Jun 30, 2026 | |||
| Insiders | 22.93% | 153.4K shares | |
| 4 holders · as of Aug 18, 2026 | |||
| Other | 6.61% | 44.2K shares | |
| remainder | |||
668.8K company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Kalehua Capital Management LLCInstitution | 35.28% | 1.65M | as of Jun 30, 2026 |
Peter M. HechtInsiderdirector, 10 percent owner | 19.44% | 130,034 | filed Jul 20, 2026 |
FMR LLCInstitution | 13.88% | 649,547 | as of Jun 30, 2026 |
Balyasny Asset Management L.P.Institution | 6.78% | 317,511 | as of Jun 30, 2026 |
Adar1 Capital Management, LLCInstitution | 6.38% | 298,757 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Johnson & Johnson
Direct TRD alternative through Spravato's supervised esketamine therapy.
- Eli Lilly
Approved oral Symbyax and a growing pharmacologic TRD pipeline.
- Compass Pathways (ADR)
Late-stage COMP360 psilocybin targets the same TRD population.
- Axsome Therapeutics
Auvelity and AXS-05 address resistant and broader depressive illness.
- Neuronetics
NeuroStar TMS is a non-drug interventional alternative for TRD.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cyclerion Therapeutics | $23.52 | 0.00% | $15.7M | — | — | 8.3 | +23.5% |
| Johnson & Johnson | $269.95 | +0.28% | $648.72B | 31.2 | 22.7 | 6.6 | +6.6% |
| Eli Lilly | $1,159.00 | −0.95% | $1.10T | 39.3 | 28.3 | 13.8 | +47.7% |
| Compass Pathways (ADR) | $14.18 | −4.07% | $1.99B | — | — | — | — |
| Axsome Therapeutics | $197.96 | −2.53% | $10.45B | — | 1,181.1 | 13.5 | +44.2% |
| Neuronetics | $2.90 | −0.52% | $202.5M | — | — | 1.3 | +9.1% |
| Median | 35.2 | 28.3 | 10.0 | +26.6% |